114 results
Page 4 of 6
6-K
EX-99.1
fc4 ynfffz
13 Jan 21
Current report (foreign)
4:00pm
6-K
EX-99.1
qa5d3
11 Jan 21
ObsEva Provides Update on Yselty® (Linzagolix) Clinical Development Program
7:05am
6-K
EX-99.1
nnsjsxudb8pb t5
10 Dec 20
Current report (foreign)
6:03am
6-K
EX-99.1
yo1nw pob
24 Nov 20
Current report (foreign)
6:03am
6-K
EX-99.1
ox66w743ki7sr 5i8
16 Nov 20
ObsEva SA Reports Positive Topline Results of the PROLONG Proof-of-Concept Trial of Ebopiprant (OBE022) for Treatment of Preterm Labor
6:39am
6-K
EX-99.2
verrl7m uo7w008wlc5
16 Nov 20
ObsEva SA Reports Positive Topline Results of the PROLONG Proof-of-Concept Trial of Ebopiprant (OBE022) for Treatment of Preterm Labor
6:39am
6-K
EX-1.1
aeaj8897n
8 Sep 20
ObsEva Announces $20.0 Million Underwritten Offering and Concurrent Private Placement
7:40am
424B5
uq7naj178 nhf
8 Sep 20
Prospectus supplement for primary offering
7:31am
6-K
EX-99.1
n7c8ar5o
6 Aug 20
Index to Unaudited Condensed Consolidated Financial Statements
6:53am
6-K
EX-99.2
qodd84za 2124ha
6 Aug 20
Index to Unaudited Condensed Consolidated Financial Statements
6:53am
6-K
EX-99.3
ilaw0f nn8
6 Aug 20
Index to Unaudited Condensed Consolidated Financial Statements
6:53am
6-K
EX-99.1
l62q7 j88spv9
6 Jul 20
ObsEva Announces Positive Results from two Phase 3 Studies, PRIMROSE 1 and 2, of Yselty® (linzagolix) for the Treatment of Uterine Fibroids
6:18am
6-K
EX-99.1
bsh4zf
1 Jul 20
ObsEva and Yuyuan BioScience Technology Announce Submission of the Pre-IND Dossier for Nolasiban with the Chinese NMPA
6:15am
6-K
EX-99.1
917wcp1ibip9dq4sl
5 May 20
Index to Unaudited Condensed Consolidated Financial Statements
6:01am
6-K
EX-99.2
b4hl5 qfeg
5 May 20
Index to Unaudited Condensed Consolidated Financial Statements
6:01am
6-K
EX-99.3
0ycxghn
5 May 20
Index to Unaudited Condensed Consolidated Financial Statements
6:01am
6-K
EX-99.1
gl43tei
23 Mar 20
ObsEva Provides Update Related to COVID-19 Pandemic
4:00pm